Retatrutide is an investigational once-weekly peptide developed by Eli Lilly. It operates as a “triple-agonist” by mimicking three natural hormones: GLP-1, GIP, and glucagon. In clinical trials, it has shown highly promising results, driving an average weight loss of up to 24% in obese adults
-21%
Original price was: 189 $.150 $Current price is: 150 $.